Microcrystalline cellulose membrane for re-epithelisation of chronic leg wounds: a prospective open study.
Treatment of chronic leg ulcers remains a major health care issue. Although many reports have examined different topical dressings, none have specifically looked at microcrystalline cellulose (MCC). We aimed to evaluate in a prospective, open study the safety and performance of a MCC membrane (Veloderm) in a series of chronic leg wounds of different aetiology. Fifty-five patients participated in this study. The membrane was applied every 5-10 days for 1 month, immediately after surgical debridement. The wound bed was assessed on days 7, 15 and 30 for erythema, pain, exudate level and infection. The wound size change at 30 days was the primary efficacy parameter and any adverse events were collected and analysed. A wound size change of 55% was achieved at the end of follow-up, with an improvement in all the collected parameters, but the erythema, which showed a mild increase. To date, this is the largest experience with a MCC product in chronic wounds. Our study suggests that this treatment may be safe and useful and deserves further investigation.
Ricci
Elia B
EB
U. O. A. Ferite Difficili, Casa di Cura San Luca, Turin, Italy.
Cassino
Roberto
R
Di Campli
Cristiana
C
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003646:Debridement; D004890:Erythema / Q000209:etiology; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D011134:Polysaccharides / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index; D017592:Skin Care / Q000379:methods*; D016896:Treatment Outcome; D014945:Wound Healing; D014946:Wound Infection / Q000209:etiology
D011134:Polysaccharides; C007916:hemicellulose